-
2023-505163-37-00
3
2021-10-01
Metastatic Colorectal Cancer
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-514548-10-01
3
2021-07-26
Mild to moderate atopic dermatitis
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-509357-31-00
1
2021-06-01
Multiple Sclerosis (MS)
-
2022-502519-13-00
5
2021-05-07
Moderate to Severe Plaque Psoriasis
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-514010-12-00
1
2020-12-03
Advanced Malignancies
-
2024-516649-38-00
5
2020-12-01
Recurrent ovarian, fallopian tube or primary peritoneal cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2024-515114-41-00
7
2020-08-10
Solid tumors
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-513100-34-00
1
2020-07-15
Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressin
-
2024-514892-16-00
6
2020-05-05
Diarrhoea predominant irritable bowel syndrome
-
2023-504653-12-00
4
2020-02-10
Patients with previously untreated Richter Transformation or patients
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)